Corticosteroids for pneumonia

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Yuanjing, Chen ^a   Pu, Hongshan ^a   Wu, Taixiang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID;

ASSISTED VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HOSPITAL DISCHARGE; HUMAN; INOTROPISM; INTENSIVE CARE UNIT; MORTALITY; OUTCOME ASSESSMENT; OXYGENATION; PNEUMONIA; RELAPSE; REVIEW;

EID: 70349146752     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007720     Document Type: Review

References (16)

1. Adcock IM, Ito K. Molecular mechanisms of corticosteroid actions. Monaldi Archives for Chest Disease 2000;256(3):66.
2. d'Escrivan T, Guery B. Prevention and treatment of aspiration pneumonia in intensive care units. Treatments in Respiratory Medicine 2005;4(5):317-324
3. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple graphical test. BMJ 1997;315:629-634 (Pubitemid 27387172)
4. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. European Respiratory Journal 2007;30(5):951-956 (Pubitemid 351194800)
5. Gerald L, Mandell JE, Bennett DR. Mandell's Principles and Practices of Infection Diseases. 6th Edition. Vol. 4016, Churchill Livingstone, 2004.
6. Higgins JPT, Green S. Application of quality assessment criteria. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. (Available from www.cochrane-hand- book.org). Chichester, UK: John Wiley & Sons, Ltd, 2008.
7. Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. BMJ 2006;332:3.
8. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice. 1997 CFR & ICH Guidelines. 1st Edition. Vol. 1, PA, USA: Barnett International/PAREXEL, 1997.
9. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). (Available from www.cochrane-handbook.org). Chichester, UK: Wiley-Blackwell, 2008.
10. Leroy O, Soubrier S. Hospital-acquired pneumonia: risk factors, clinical features, management, and antibiotic resistance. Infectious Diseases 2004;10(3):171-175
11. Ostapchuk M, Roberts DM, Haddy R. Community-acquired pneumonia in infants and children. American Family Physician 2004;70 (5):899-908.
12. Plouffe JF, Herbert MT, File TM Jr, Baird I, Parsons JN, Kahn JB, et al.Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrobial Agents and Chemotherapy 1996;40:5. (Pubitemid 26136030)
13. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
14. Seale JP, Compton MR. Side-effects of corticosteroid agents. The Medical Journal of Australia 1986;144(3):139-142
15. Wipf JE, Lipsky BA, Hirschmann JV, Boyko EJ, Takasugi J, Peugeot RL, et al.Diagnosing pneumonia by physical examination: relevant or relic?. Archives of Internal Medicine 1999;159(10):1082-1087 (Pubitemid 29230860)
16. Wu T, Liu G. The concepts, design, practice and report of allocation concealment and blinding. Chinese Journal of Evidence-Based Medicine 2007;7(3):203-7.